Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab phase 3 study in generalized myasthenia gravis
NL-OMON54231Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of satralizumab in myasthenia gravis (MG) (3 arms), sponsored by Roche. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
satralizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON54231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54231.